Clinical Trial Update: Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris [Phase 2]

View source ↗

Summary

This Phase 2 trial assesses safety and biomarker responses to delgocitinib, a JAK1/2/3/TYK2 inhibitor, in Central Centrifugal Cicatricial Alopecia and Lichen Pl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Centrifugal Cicatricial Alopecia
• Lichen Planopilaris

Drugs mentioned

• delgocitinib (delgocitinib)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Central Centrifugal Cicatricial Alopecia, Lichen Planopilaris | Phase 2 | Status: NOT_YET_RECRUITING